AN IN VITRO TEST PREDICTIVE OF THE IN VIVO B CELL RITUXIMAB-TRIGGERED DEPLETION, UNDERLINES THE POTENTIAL THERAPEUTIC INTEREST OF A RECOMBINANT ANTI-CD20 IGA IN B-CLL PATIENTS

被引：0
|
作者：
Congy, N. [1 ]
Ysebaert, L. [2 ]
Apoil, P. [1 ]
Tiraby, G. [3 ]
Drocourt, D. [3 ]
Abbal, M. [1 ]
Blancher, A. [1 ]
机构：
[1] Univ Paul Sabatier, EA 3O34, Toulouse, France
[2] CHU Purpan, INSERM, U563, Toulouse, France
[3] Cayla Invivogen, Toulouse, France
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1263
引用
收藏
页码：515 / 515
页数：1
相关论文
共 50 条
  • [1] In vitro sensitivity of B-CLL cells to fludarabine, anti-CD20 (rituximab) and anti-CD52 (Campath-1H).
    Grdisa, M
    Ajchenbaum-Cymbalista, F
    Tang, RP
    Marie, JP
    Delmer, A
    BLOOD, 2000, 96 (11) : 161A - 161A
  • [2] Short term in vivo activity of Rituximab anti CD20 monoclonal antibody in B-CLL patients.
    Berchem, GJ
    Heintz, D
    Bosseler, M
    Duhem, C
    Ries, F
    Dicato, MA
    BLOOD, 1999, 94 (10) : 307B - 307B
  • [3] B-cell depletion in patients with multiple myeloma with the anti-CD20 monoclonal antibody rituximab after high dose therapy
    Witzens, M
    Gemmel, C
    Moos, M
    Goldschmidt, H
    Ho, AD
    BONE MARROW TRANSPLANTATION, 1999, 23 : S141 - S141
  • [4] Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series
    Øystein Fluge
    Olav Mella
    BMC Neurology, 9
  • [5] Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series
    Fluge, Oystein
    Mella, Olav
    BMC NEUROLOGY, 2009, 9
  • [6] Severe side effects in patients with B-cell chronic lymphocytic leukemia (CLL) and lymphocytosis treated with the monoclonal anti-CD20 antibody rituximab.
    Winkler, U
    Jensen, M
    Manzke, O
    Tesch, H
    Bohlen, H
    Diehl, V
    Engert, A
    BLOOD, 1998, 92 (10) : 285B - 285B
  • [7] A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
    R Eisenberg
    D Albert
    J Stansberry
    D Tsai
    S Kolasinski
    S Khan
    Arthritis Res Ther, 5
  • [8] A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus
    Eisenberg, R
    Albert, D
    Stansberry, J
    Tsai, D
    Kolasinski, S
    Khan, S
    ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 3) : S9 - S10
  • [9] Ibrutinib Exposure and B-Cell Depletion Induced By Anti-CD20 Monoclonal Antibodies Rituximab and Obinutuzumab: Is There a Rationale for Combination Studies?
    Ysebaert, Loic
    Klein, Christian
    Quillet-Mary, Anne
    BLOOD, 2014, 124 (21)
  • [10] Targeted B-cell depletion using rituximab (anti-CD20) in recalcitrant autoimmune urticaria: Efficacy, safety, and mechanisms of action
    Bingham, C. O., III
    Jones, P. E.
    Gober, L. M.
    Eckman, J. A.
    Sterba, P. M.
    Saini, S. S.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (02) : S172 - S172
12345